SSRI enhances sensitivity to background outcomes and modulates response rates: A randomized double blind study of instrumental action and depression

被引:11
|
作者
Msetfi, Rachel M. [1 ,2 ]
Kumar, Poornima [3 ]
Harmer, Catherine J. [4 ]
Murphy, Robin A. [5 ]
机构
[1] Univ Limerick, Dept Psychol, Ctr Social Issues Res, Limerick, Ireland
[2] Univ Limerick, Hlth Res Inst, Limerick, Ireland
[3] Harvard Univ, McLean Hosp, Sch Med, Ctr Depress Anxiety & Stress Res, Belmont, MA USA
[4] Univ Oxford, Dept Psychiat, Oxford, England
[5] Univ Oxford, Dept Expt Psychol, S Parks Rd, Oxford OX1 3UD, England
关键词
Escitalopram; SSRI; Serotonin; Learning; Perceived control; Context; Response rate; Depression; ACUTE TRYPTOPHAN DEPLETION; CONTINGENCY JUDGMENTS; PREFRONTAL CORTEX; DOPAMINE NEURONS; SEROTONIN; ANTIDEPRESSANTS; INFORMATION; INHIBITION; INVENTORY; RECEPTOR;
D O I
10.1016/j.nlm.2016.03.004
中图分类号
B84 [心理学]; C [社会科学总论]; Q98 [人类学];
学科分类号
03 ; 0303 ; 030303 ; 04 ; 0402 ;
摘要
Serotonin reuptake inhibitors (SSRIs) have immediate effects on synaptic levels of serotonin but their therapeutic effects are often delayed. This delay has been suggested to reflect time required for new learning and therefore that SSRIs might be having effects on the learning process. We examined the effects of elevating serotonin levels, through short-term SSRI administration (escitalopram), on learning about perceptions of instrumental control. A randomised double blind procedure was used to allocate healthy people, categorised as mildly depressed (high BDI >= 10: n = 76) or not depressed (low BDI <= 5: n = 78) to either a drug (escitalopram, 10 mg/7 days) or placebo control group. Following treatment, participants were trained with a simple task that involved learning the effectiveness of an instrumental action (key press) and the background context at eliciting an outcome (auditory cue) where there was no programmed contingency. The effects of the drug were (i) to moderate response rates and (ii) to enhance sensitivity to the background or context rate of occurrence of the outcome. These findings suggest that serotonin modulates learning about the long-term rate of outcomes, which supports perception of instrumental control, and that this may provide a clue to the mechanism for supporting the development of the therapeutic effects of the drug. (C) 2016 The Authors. Published by Elsevier Inc.
引用
收藏
页码:76 / 82
页数:7
相关论文
共 31 条
  • [21] Randomized, double-blind, placebo-controlled, multicentre pilot study on the effects of empagliflozin on clinical outcomes in patients with acute decompensated heart failure (EMPA-RESPONSE-AHF)
    Damman, Kevin
    Beusekamp, Joost C.
    Boorsma, Eva M.
    Swart, Henk P.
    Smilde, Tom D. J.
    Elvan, Arif
    van Eck, J. W. Martijn
    Heerspink, Hiddo J. L.
    Voors, Adriaan A.
    EUROPEAN JOURNAL OF HEART FAILURE, 2020, 22 (04) : 713 - 722
  • [22] 12-month Findings of the Randomized, Double-Blind, Placebo-Controlled, Multicenter, Efficacy and Safety Study of Methotrexate to Increase Response Rates in Patients with Uncontrolled GOut Receiving Pegloticase (MIRROR RCT)
    Botson, John
    Saag, Kenneth
    Peterson, Jeff
    Obermeyer, Katie
    LaMoreaux, Brian
    Grewal, Suneet
    Majjhoo, Amar
    Tesser, John
    Weinblatt, Michael
    ARTHRITIS & RHEUMATOLOGY, 2022, 74 : 1 - 2
  • [23] Response, remission and drop-out rates following high-frequency repetitive transcranial magnetic stimulation (rTMS) for treating major depression: a systematic review and meta-analysis of randomized, double-blind and sham-controlled trials
    Berlim, M. T.
    van den Eynde, F.
    Tovar-Perdomo, S.
    Daskalakis, Z. J.
    PSYCHOLOGICAL MEDICINE, 2014, 44 (02) : 225 - 239
  • [24] IMPROVED PATIENT-REPORTED OUTCOMES (PROS) WITH MIRABEGRON ADD-ON TREATMENT IN A RANDOMIZED, DOUBLE-BLIND, PHASE 3B STUDY IN INCONTINENT OVERACTIVE BLADDER (OAB) PATIENTS WITH AN INADEQUATE RESPONSE TO SOLIFENACIN
    MacDiarmid, Scott
    Al-Shukri, Salman
    Barkin, Jack
    Fianu-Jonasson, Aino
    Grise, Philippe
    Herschorn, Sender
    Huang, Moses
    Siddiqui, Emad
    Stolzel, Matthias
    Hemsted, Claire
    Drake, Marcus
    JOURNAL OF UROLOGY, 2016, 195 (04): : E849 - E849
  • [25] A phase III, randomized, double-blind, placebo (PBO)-controlled study of enzalutamide (ENZA) in men with nonmetastatic castration-resistant prostate cancer (nmCRPC): Outcomes by prostate-specific antigen (PSA) response
    Hussain, M.
    Sternberg, C. N.
    Efstathiou, E.
    Fizazi, K.
    Shen, Q.
    Lin, X.
    Sugg, J.
    Steinberg, J.
    Noerby, B.
    De Giorgi, U.
    Shore, N.
    Saad, F.
    ANNALS OF ONCOLOGY, 2020, 31 : S544 - S545
  • [26] Effects of Galcanezumab on Acute Medication Use, Time to Response, and Total Pain Burden in Patients with Episodic Cluster Headache: Post hoc Outcomes from a Phase 3, Randomized, Double-blind, Placebo-controlled Study
    Kudrow, David
    Andrews, J. Scott
    Rettiganti, Mallikarjuna
    Oakes, Tina
    Bardos, Jennifer
    Zhou, Chunmei
    Aurora, Sheena K.
    Kuruppu, Dulanji
    Wenzel, Richard
    Riesenberg, Robert
    Gaul, Charly
    Martinez, James
    NEUROLOGY, 2020, 94 (15)
  • [27] Sustained Response Outcomes from a Phase 2a, Randomized, Double-blind, Placebo-controlled Study of LY2951742, a Monoclonal Antibody to Calcitonin Generelated Peptide, for the Prevention of Migraine: A Post-hoc Analysis
    Dodick, D. W.
    Goadsby, P. J.
    Ferguson, M.
    Oakes, T.
    Tanaka, Y.
    Ni, X.
    Zhang, Q.
    Due, M.
    Skljarevski, V
    Martinez, J.
    HEADACHE, 2015, 55 : 177 - 177
  • [28] Patient-reported outcomes from a randomized, double-blind, placebo controlled, phase III study of baricitinib versus placebo in patients with moderately to severely active rheumatoid arthritis and an inadequate response to methotrexate therapy: results from the RA-BALANCE study
    Yang, Yue
    Xu, Jianhua
    Xu, Jian
    Li, Xingfu
    Hu, Jiankang
    Li, Xiangpei
    Zhang, Xiao
    He, Dongyi
    Bao, Chunde
    Li, Zhijun
    Wang, Guochun
    Zerbini, Cristiano A. F.
    Spindler, Alberto J.
    Kannowski, Carol L.
    Wu, Hanjun
    Ji, Fei
    Zhan, Lujing
    Liu, Mengru
    Li, Zhanguo
    THERAPEUTIC ADVANCES IN MUSCULOSKELETAL DISEASE, 2021, 13
  • [29] Sustained response outcomes from a phase 2a, randomized, double-blind, placebo-controlled study of LY2951742, a monoclonal antibody to calcitonin gene-related peptide, for the prevention of migraine: a post-hoc analysis
    Dodick, D. W.
    Goadsby, P. J.
    Skljarevski, V.
    Ferguson, M.
    Oakes, T.
    Tanaka, Y.
    Ni, X.
    Zhang, Q.
    Due, M.
    Martinez, J.
    CEPHALALGIA, 2015, 35 : 52 - 52
  • [30] A TRI-ANTIGENIC HEPATITIS B VACCINE (TAV) PROVIDES CONSISTENTLY HIGHER SEROPROTECTION RATES (SPR) AND ANTI-HBS TITERS IN ALL SUBJECTS, INCLUDING THOSE KNOWN TO HAVE A REDUCED IMMUNE RESPONSE TO A MONO-ANTIGENIC VACCINE: RESULTS FROM THE PHASE 3 DOUBLE-BLIND, RANDOMIZED STUDY (PROTECT)
    Langley, Joanne
    Vesikari, Timo
    Segall, Nathan
    Ward, Brian J.
    Cooper, Curtis
    Poliquin, Guillaume
    Gantt, Soren
    Smith, Bruce
    Van Demme, Pierre
    Leroux-Roels, Isabel
    Leroux-Roels, Geert
    Machluf, Nathalie
    Spaans, Johanna
    Yassin-Rajkumar, Bebi
    Anderson, David E.
    Popovic, Vladimir
    Diaz-Mitoma, Francisco
    HEPATOLOGY, 2020, 72 : 451A - 451A